Lobbying firms with close ties to Trump, such as Checkmate Government Relations, Miller Strategies and Ballard Partners, have seen significant increases in business in the first year of President Trump's second term[1]. Pharmaceutical giants are increasing spending on these firms due to new risks and opportunities related to White House policies[1]. Most of the 16 companies that entered into drug price agreements with the White House contracted with just one of these three firms[1]. The Trump administration is introducing political priorities to the Food and Drug Administration (FDA), which has so far protected it from such influence[2]. The pharmaceutical industry is taking advantage of these new lobbying opportunities through lobbyists, advisors, FDA officials, and managers[2]. According to Michael Abrams of Numerof and Associates, the nature of the relationship between firms and the administration has changed significantly, with discussions of FDA decisions now common[2].